Comparison of Clinical Evidence Submitted to the FDA and EMA for Cell and Gene Therapies.
No abstract available
References:
Mission: harmonisation for better health. International Council for Harmonisation . Accessed June 6, 2024. https://www.ich.org/page/mission
CY 2023 report from the director. US Food and Drug Administration . Accessed June 6, 2024. https://www.fda.gov/vaccines-blood-biologics/cy-2023-report-director
Approved cellular and gene therapy products. US Food and Drug Administration . Accessed June 6, 2024. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
European public assessment reports: background and context. European Medicines Agency . Accessed June 6, 2024. https://www.ema.europa.eu/en/medicines/what-we-publish-medicines-and-when/european-public-assessment-reports-background-and-context#publications-19138
Elsallab M, Bravery CA, Kurtz A, Abou-El-Enein M. Mitigating deficiencies in evidence during regulatory assessments of advanced therapies: a comparative study with other biologicals. Mol Ther Methods Clin Dev. 2020;18:269-279. doi:10.1016/j.omtm.2020.05.035